Ernexa Therapeutics Inc. Proceeds from Convertible Debt
Ernexa Therapeutics Inc. (ERNA) reported Proceeds from Convertible Debt of $1.41 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2026-03-13
- Ernexa Therapeutics Inc. proceeds from convertible debt for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. proceeds from convertible debt for the quarter ending 2024-09-30 was $0.00.
- Ernexa Therapeutics Inc. proceeds from convertible debt for the quarter ending 2024-06-30 was $0.00.
- Ernexa Therapeutics Inc. proceeds from convertible debt for the quarter ending 2024-03-31 was $1.41M.
- Ernexa Therapeutics Inc. proceeds from convertible debt for fiscal 2024 was $1.41M, a 91.49% decline from fiscal 2023.
- Ernexa Therapeutics Inc. proceeds from convertible debt for fiscal 2023 was $16.50M.
- Ernexa Therapeutics Inc. proceeds from convertible debt for fiscal 2022 was $0.00.
| Period end | Proceeds from Convertible Debt | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-13 | $0.00 derived: sum of 3 quarters · filed 2026-03-13 | $1.41M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $1.41M 10-Q · filed 2025-11-07 | $9.19M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.41M 10-Q · filed 2025-08-13 | $9.19M derived: sum of 3 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $1.41M 10-Q · filed 2025-05-07 | $9.19M derived: sum of 2 quarters · filed 2025-05-07 | |||
| 2024-01-11 | $1.41M 10-K · filed 2025-03-12 | ||||
| 2023-12-31 | $7.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $16.50M 10-K · filed 2025-03-12 | |||
| 2023-12-15 | $7.79M 10-K · filed 2025-03-12 | ||||
| 2023-09-30 | $8.71M 10-Q · filed 2024-11-12 | ||||
| 2023-07-14 | $8.71M 10-K · filed 2025-03-12 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |